Nearly 150 million Americans live in states with full medical marijuana programs, and over 17 million live in states with legal recreational marijuana. Yet, according to Governance Studies Fellow John Hudak, the federal government lags behind in its policies and regulations governing marijuana use and research.
A new Brookings short film examines the convoluted state of marijuana policy, and illustrates the human consequences of laws that limit the research and availability of medical cannabis (CBD). In a scene shot at a marijuana growing facility, the facility operator explains the motivations behind his family’s business: “We talk to mothers that have epileptic children, kids who have 50 seizures a day. And with the CBD medicine we make, they went from 50 to zero. Zero seizures. They’re in school, they’re playing soccer. To see the emotion that comes from that was a big impetus for us.” Rabbi Jeffrey Kahn who operates the dispensary in the nation’s capital that is also featured in the film, reports that “We see people with just about every condition from just about every walk of life who find relief from medical marijuana.”
Federal policies governing cannabis use and research in the United States are contradictory, explains Hudak. With marijuana classified as a Schedule I substance, along with heroin and ecstasy, the federal government “makes medical research on a product that is continually and frequently prescribed for medicinal use all that much harder.”
In addition, the U.S. Department of Justice considers marijuana enterprises legal to operate as long as they obey state regulations and other laws, while the Internal Revenue Service considers them to be criminal organizations. “The Department of Justice and the IRS are right across the street from each other in Washington, DC, but on policy they are miles apart,” Hudak says. “Which one is right? Right now, it’s both,” he adds, before imploring the president, Congress, and federal officials to “take ownership of the disconnected set of policies, laws, and regulations that make it confusing for states and for marijuana enterprises to go on.”
“Either marijuana is illegal, or it’s legal and regulated. But it can’t be both,” Hudak declares.
Read more from Brookings experts about marijuana policy and regulatory reform:
See an archive of all Brookings research and commentary on marijuana policy.
The Duque government’s drug policy in Colombia is taking on a progressively ominous and counterproductive direction. It threatens to undermine the incomplete and struggling peace process, misdirect law enforcement resources, augment the alienation of coca farmers from the state and undermine human rights and drug users’ access to health services in Colombia. With their emphasis on criminalization of even drug possession for personal use and forced eradication, the announced policies clearly cater to the Trump administration’s doctrinaire and discredited drug policy preferences that harken back to the 1980s. But without sustainable livelihoods already in place, forced eradication will not sustainably reduce coca cultivation and cocaine production. The dominance of zero-coca thinking in Colombia whereby a community has to eradicate all coca first before it starts receiving even meager assistance from the state never produced positive results in Colombia.